In response to:

Don't Let Obama Kill "Pills for Profit"

girl buddy Wrote: Jan 29, 2013 8:03 AM
We should, however, put a kibosh on all the anti-depressant and psychotropic drugs that are strongly associated with killing sprees, murders and suicides. The association is undeniable. Where is the public debate on this?
Wumingren Wrote: Jan 29, 2013 9:59 AM
There was a little bit revealed about the high suicide rate of today's veterans, and one of the things that is statistically important is the anti-smoking campaign in the military. In the military you don't own your own body and can experience non-judicial punishment for simply getting a severe sunburn due to stupidly falling asleep on the beach. So, when they tell you to quit smoking and give you Champix or Chantix, you take it to stop smoking. Unfortunately, these drugs are linked with increased depression and suicide. The media fails to make an issue of it, even though they dislike pharaceutical companies, I guess they dislike the military more.
Wumingren Wrote: Jan 29, 2013 10:04 AM
But drugs that affect the brain like this are being pumped into our children and young adults at an alarming rate. Even though these drugs increase thoughts of suicide and murder, they are still given to our kids. It is likely that the majority of school shootings were perpetrated by people that were either on these drugs or had recently stopped taking them (withdrawal can aggrevate the brain as much or more than initial dosing). The media fails to make an issue of it, even though they dislike pharmaceutical compaies, I guess they just dislike firearms more.
pow1000 Wrote: Jan 29, 2013 9:08 AM
The public? Not, there should be a debate in the medical circle.

Biotech company Excelixis CEO George Scangos likes to quote oil wildcatter JP Getty when asked about his philosophy for success: “Get up early; work hard; find oil,” he deadpans.

And under the direction of dry-humored Scangos, the San Francisco-based company is drilling a lot of research holes, so to speak.

They have to: Success in the biotech industry is measured incrementally, not in big steps. It’s a cash-and-time intensive industry where success is painstaking, rare and, because of Obamacare and other regulatory burdens from the administration, likely to become even rarer.   

According to Plunkett Research, Ltd in 2010 it...

Related Tags: Obama